Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

ELIQUIS Film-coated tablets (2018)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Eliquis 2.5 mg film-coated tablets.

Qualitative and quantitative composition

Each film-coated tablet contains 2.5 mg apixaban. Excipients with known effect: Each 2.5 mg film-coated tablet contains 51.43 mg lactose (see section 4.4). For the full list of excipients, see section ...

Pharmaceutical form

Film-coated tablet (tablet). Yellow, round tablets debossed with 893 on one side and 2 1⁄2 on the other side.

Therapeutic indications

Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular ...

Posology and method of administration

Posology Prevention of VTE (VTEp): elective hip or knee replacement surgery The recommended dose of apixaban is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery. ...

Contraindications

*Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Active clinically significant bleeding. Hepatic disease associated with coagulopathy and clinically relevant ...

Special warnings and precautions for use

Haemorrhage risk As with other anticoagulants, patients taking Eliquis are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of ...

Interaction with other medicinal products and other forms of interaction

Inhibitors of CYP3A4 and P-gp Coadministration of apixaban with ketoconazole (400 mg once a day), a strong inhibitor of both CYP3A4 and P-gp, led to a 2-fold increase in mean apixaban AUC and a 1.6-fold ...

Fertility, pregnancy and lactation

Pregnancy There are no data from the use of apixaban in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Apixaban is not recommended ...

Effects on ability to drive and use machines

Eliquis has no or negligible influence on the ability to drive and use machines.

Undesirable effects

Summary of the safety profile The safety of apixaban has been investigated in 7 Phase III clinical studies including more than 21,000 patients: more than 5,000 patients in VTEp studies, more than 11,000 ...

Overdose

There is no antidote to Eliquis. Overdose of apixaban may result in a higher risk of bleeding. In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. ...

Pharmacodynamic properties

Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors ATC code: B01AF02 Mechanism of action Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor ...

Pharmacokinetic properties

Absorption The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg. Apixaban is rapidly absorbed with maximum concentrations (C<sub>max</sub>) appearing 3 to 4 hours after tablet ...

Preclinical safety data

Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, fertility and embryo-foetal development ...

List of excipients

Tablet core: Anhydrous lactose Microcrystalline cellulose (E460) Croscarmellose sodium Sodium laurilsulfate Magnesium stearate (E470b) Film coat: Lactose monohydrate Hypromellose (E464) Titanium dioxide ...

Incompatibilities

Not applicable.

Shelf life

Shelf life: 3 years.

Special precautions for storage

This medicinal product does not require any special storage condition.

Nature and contents of container

Alu-PVC/PVdC blisters. Cartons of 10, 20, 60, 168 and 200 film-coated tablets. Alu PVC/PVdC perforated unit dose blisters of 60x1 and 100x1 film-coated tablets. Not all pack sizes may be marketed.

Special precautions for disposal and other handling

No special requirements. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Marketing authorization holder

Bristol-Myers Squibb/Pfizer EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, United Kingdom

Marketing authorization number(s)

EU/1/11/691/001 EU/1/11/691/002 EU/1/11/691/003 EU/1/11/691/004 EU/1/11/691/005 EU/1/11/691/013 EU/1/11/691/015

Date of first authorization / renewal of the authorization

Date of first authorisation: 18 May 2011 Date of latest renewal: 14 January 2016

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: